Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

These tumors, known as adenomas, produce a hormone called aldosterone that raises blood pressure and can cause other cardiovascular problems. Adrenal tumors include nonfunctional adenomas (NFAs), ...

Single-nucleus RNA sequencing of 2 nonfunctional adenomas and 3 aldosterone-producing adenomas revealed 13 clusters (Upper). Pseudotime course analysis predicted the transition of two cell fates in ...

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...

Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension (RH). Agents such as baxdrostat, the first selective aldosterone ...

A novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase ...

Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...